Catalent, Inc. (NYSE: CTLT), the leading global provider of
advanced delivery technologies, development, and manufacturing
solutions for drugs, biologics, cell and gene and therapies, and
consumer health products, today published its Corporate
Responsibility (CR) Report for fiscal year 2020. The report covers
environmental, social, and governance (ESG) topics relevant to
Catalent’s business, charting the company’s performance against the
Sustainability Accounting Standards Board (SASB) standard for the
biotechnology and pharmaceutical industries.
Building on the foundation laid with Catalent’s first CR report
in 2020 (covering fiscal 2019), which set out goals in areas such
as energy efficiency, diversity and inclusion, and community
investment, this new report highlights the progress made in a year
when the company, and the biotechnology and pharmaceutical
industries in general, focused on responding to the global COVID-19
pandemic.
“Our 2020 fiscal year was an extraordinarily challenging period
for everyone, but it allowed us to demonstrate the importance of
our corporate responsibility commitment. At the heart of this
commitment is Catalent’s “Patient First” philosophy, which has been
fundamental to our work developing and manufacturing so many
COVID-19 vaccines and treatments for customers as part of the fight
against the worldwide pandemic,” commented John Chiminski, Chair
and Chief Executive Officer of Catalent. He added, “I am incredibly
proud that, throughout these most challenging of times, we have
continued to prioritize the needs of people and patients, in line
with our values and culture. This, our second corporate
responsibility report, continues to formalize our progress in this
area, supporting Catalent’s aim to be the world’s most trusted,
reliable, and innovative drug development partner.”
Highlights of the report include wider sustainability
commitments that now include water-efficiency and waste-reduction
targets, and a goal for all sites to discharge wastewater with API
concentrations below Predicted No-Effect Concentration (PNEC)
levels by fiscal 2024. Additionally, 50 projects focusing on energy
efficiency at Catalent’s global facilities were completed through
the end of the 2020 fiscal year, with six Catalent sites
transitioning to 100 percent renewable electricity sources. In
fiscal 2020, the company also developed a human rights statement
and expanded its diverse recruiting and talent development
partnerships. It also established a well-being forum and adapted
how it communicates with its employees, adopted more flexible work
practices, and increased mental health and family initiatives, in
part to account for the effects of the COVID-19 pandemic on its
workforce. The “Catalent Cares” community giving and volunteer
program that was launched in fiscal 2018 to strengthen employees’
ability to give back to society has seen 500 non-profit
organizations benefit in fiscal 2020, alongside a number of
COVID-19 grants made to communities in need.
The fiscal 2020 Catalent Corporate Responsibility report is
available at
https://www.catalent.com/about-us/corporate-responsibility/, and
further information can be requested by contacting
corporateresponsibility@catalent.com.
Notes for Editors
About Catalent, Inc.
Catalent, Inc. (NYSE: CTLT), an S&P 500® company, is the
leading global provider of advanced delivery technologies,
development, and manufacturing solutions for drugs, biologics, cell
and gene therapies, and consumer health products. With over 85
years serving the industry, Catalent has proven expertise in
bringing more customer products to market faster, enhancing product
performance and ensuring reliable global clinical and commercial
product supply. Catalent employs approximately 15,000 people,
including around 2,400 scientists and technicians, at more than 45
facilities, and in fiscal year 2020 generated over $3 billion in
annual revenue. Catalent is headquartered in Somerset, New Jersey.
For more information, visit www.catalent.com
More products. Better treatments. Reliably supplied.™
Forward-Looking Statements
This release contains both historical and forward-looking
statements. All statements other than statements of historical
fact, are, or may be deemed to be, forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. These forward-looking statements generally can be
identified by the use of statements that include phrases such as
“believe,” “expect,” “anticipate,” “intend,” “estimate,” “plan,”
“project,” “foresee,” “likely,” “may,” “will,” “would,” or other
words or phrases with similar meanings. Similarly, statements that
describe Catalent’s objectives, plans, or goals are, or may be,
forward-looking statements. These statements are based on current
expectations of future events. If underlying assumptions prove
inaccurate or unknown risks or uncertainties materialize, actual
results could vary materially from Catalent’s expectations and
projections. Some of the factors that could cause actual results to
differ include, but are not limited to, the following: the current
or future effects of the COVID-19 pandemic on Catalent's and its
clients' businesses; participation in a highly competitive market
and increased competition that may adversely affect Catalent’s
business; demand for its offerings, which depends in part on its
customers’ research and development and the clinical and market
success of their products; product and other liability risks that
could adversely affect Catalent’s results of operations, financial
condition, liquidity and cash flows; failure to comply with
existing and future regulatory requirements; failure to provide
quality offerings to customers could have an adverse effect on
Catalent’s business and subject it to regulatory actions and costly
litigation; problems providing the highly exacting and complex
services or support required; global economic, political and
regulatory risks to Catalent’s operations; inability to enhance
existing or introduce new technology or service offerings in a
timely manner; inadequate patents, copyrights, trademarks and other
forms of intellectual property protections; fluctuations in the
costs, availability, and suitability of the components of the
products Catalent manufactures, including active pharmaceutical
ingredients, excipients, purchased components and raw materials;
changes in market access or healthcare reimbursement in the United
States or internationally; fluctuations in the exchange rate of the
U.S. dollar against other currencies, including as a result of the
U.K.’s exit from the European Union; adverse tax legislative or
regulatory initiatives or challenges or adjustments to Catalent’s
tax positions; loss of key personnel; risks generally associated
with information systems; inability to complete any future
acquisitions or other transactions that may complement or expand
its business or divest of non-strategic businesses or assets and
difficulties in successfully integrating acquired businesses and
realizing anticipated benefits of such acquisitions; risks
associated with timely and successfully completing, and correctly
anticipating the future demand predicted for, capital expansion
projects at existing facilities, offerings and customers’ products
that may infringe on the intellectual property rights of third
parties; environmental, health and safety laws and regulations,
which could increase costs and restrict operations; labor and
employment laws and regulations or labor difficulties, which could
increase costs or result in operational disruptions; additional
cash contributions required to fund Catalent’s existing pension
plans; substantial leverage that may limit its ability to raise
additional capital to fund operations and react to changes in the
economy or in the industry; exposure to interest-rate risk to the
extent of its variable-rate debt preventing it from meeting its
obligations under its indebtedness; and changes to environmental
standards, guidance, or related technological capabilities that may
render it more expensive or more difficult to reach environmental
goals. For a more detailed discussion of these and other factors,
see the information under the caption “Risk Factors” in Catalent’s
Annual Report on Form 10-K for the fiscal year ended June 30, 2020,
filed August 31, 2020. All forward-looking statements speak only as
of the date of this release or as of the date they are made, and
Catalent does not undertake to update any forward-looking statement
as a result of new information or future events or developments
except to the extent required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210513005182/en/
Media Contacts:
Chris Halling +44 (0)7580 041073 chris.halling@catalent.com
Richard Kerns +44 (0)161 728 5880 richard@nepr.agency
Investor Relations:
Paul Surdez +1 (732)537 6325 investors@catalent.com
Catalent (NYSE:CTLT)
Historical Stock Chart
From Feb 2024 to Mar 2024
Catalent (NYSE:CTLT)
Historical Stock Chart
From Mar 2023 to Mar 2024